Renaissance Technologies LLC Buys 9,300 Shares of Tarsus Pharmaceuticals, Inc. $TARS

Renaissance Technologies LLC increased its stake in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) by 14.5% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 73,400 shares of the company’s stock after purchasing an additional 9,300 shares during the period. Renaissance Technologies LLC’s holdings in Tarsus Pharmaceuticals were worth $5,149,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also recently added to or reduced their stakes in the company. Gabelli Funds LLC acquired a new stake in shares of Tarsus Pharmaceuticals in the 1st quarter valued at about $253,000. Pale Fire Capital SE boosted its position in shares of Tarsus Pharmaceuticals by 130.5% during the first quarter. Pale Fire Capital SE now owns 5,652 shares of the company’s stock worth $396,000 after buying an additional 3,200 shares during the period. Lido Advisors LLC bought a new position in shares of Tarsus Pharmaceuticals during the first quarter worth about $1,710,000. First Trust Advisors LP grew its holdings in shares of Tarsus Pharmaceuticals by 10.0% during the first quarter. First Trust Advisors LP now owns 122,911 shares of the company’s stock worth $8,622,000 after buying an additional 11,141 shares in the last quarter. Finally, PNC Financial Services Group Inc. raised its position in Tarsus Pharmaceuticals by 367.1% in the 1st quarter. PNC Financial Services Group Inc. now owns 710 shares of the company’s stock valued at $50,000 after buying an additional 558 shares during the last quarter. Institutional investors own 90.01% of the company’s stock.

Tarsus Pharmaceuticals Trading Up 6.6%

Shares of Tarsus Pharmaceuticals stock opened at $65.33 on Friday. The stock has a market cap of $2.81 billion, a P/E ratio of -57.31 and a beta of 0.53. The company has a quick ratio of 3.71, a current ratio of 3.74 and a debt-to-equity ratio of 0.21. Tarsus Pharmaceuticals, Inc. has a 12-month low of $44.67 and a 12-month high of $85.25. The business’s 50 day moving average is $61.29 and its 200-day moving average is $64.94.

Tarsus Pharmaceuticals (NASDAQ:TARS) last released its earnings results on Thursday, August 6th. The company reported ($0.43) earnings per share for the quarter, missing the consensus estimate of ($0.19) by ($0.24). Tarsus Pharmaceuticals had a negative net margin of 9.02% and a negative return on equity of 14.19%. The firm had revenue of $173.91 million during the quarter, compared to the consensus estimate of $169.68 million. Equities research analysts predict that Tarsus Pharmaceuticals, Inc. will post -1.27 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities analysts have weighed in on TARS shares. Mizuho reduced their price target on Tarsus Pharmaceuticals from $100.00 to $98.00 and set an “outperform” rating for the company in a research report on Friday, July 31st. Oppenheimer started coverage on shares of Tarsus Pharmaceuticals in a research report on Friday, April 24th. They issued an “outperform” rating and a $98.00 price objective on the stock. Guggenheim reduced their target price on shares of Tarsus Pharmaceuticals from $90.00 to $89.00 and set a “buy” rating for the company in a report on Tuesday, July 21st. HC Wainwright reiterated a “buy” rating and issued a $88.00 price target on shares of Tarsus Pharmaceuticals in a research note on Thursday, July 9th. Finally, Wall Street Zen cut shares of Tarsus Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Sunday, July 12th. Two research analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating, two have given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $90.17.

Insider Activity

In related news, Director Katherine Goodrich sold 2,954 shares of Tarsus Pharmaceuticals stock in a transaction dated Monday, June 15th. The stock was sold at an average price of $62.08, for a total transaction of $183,384.32. Following the completion of the transaction, the director owned 2,233 shares in the company, valued at approximately $138,624.64. This trade represents a 56.95% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Bobak R. Azamian sold 10,000 shares of the business’s stock in a transaction that occurred on Wednesday, June 17th. The stock was sold at an average price of $61.55, for a total value of $615,500.00. Following the transaction, the chief executive officer directly owned 847,991 shares in the company, valued at approximately $52,193,846.05. This trade represents a 1.17% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders sold 39,850 shares of company stock worth $2,452,821. Insiders own 9.64% of the company’s stock.

Tarsus Pharmaceuticals News Summary

Here are the key news stories impacting Tarsus Pharmaceuticals this week:

• Positive Sentiment: Strategic acquisition expands the pipeline: Tarsus agreed to acquire Alkeus Pharmaceuticals for $450 million upfront, with potential total consideration of up to $800 million. The deal adds gildeuretinol (ALK-001), a Phase 3 oral treatment candidate for Stargardt disease, a sizable inherited retinal disorder with no FDA-approved therapy. The asset provides a potential blockbuster opportunity and strengthens Tarsus’ position in eye care. Tarsus Pharmaceuticals to Acquire Alkeus Pharmaceuticals and Advance Eye Care Leadership Position
• Positive Sentiment: Commercial momentum remained strong: Second-quarter XDEMVY net product sales reached $173.9 million, up more than 69% year over year and ahead of the approximately $169.7 million analyst consensus. Continued growth of the FDA-approved Demodex blepharitis treatment supports Tarsus’ ability to fund expansion and invest in its pipeline. Tarsus Reports Second Quarter 2026 Financial Results, Advances Next Phase of Growth
• Neutral Sentiment: Institutional support is mixed: Recent filings showed 112 institutions adding TARS shares while 117 reduced positions. Analysts cited in the reports maintained price targets between $88 and $105, above the recent trading level, but these targets may not fully reflect the acquisition’s execution risks.
• Negative Sentiment: Quarterly loss exceeded expectations: Tarsus reported a loss of $0.43 per share, worse than the roughly $0.19–$0.21 consensus loss, despite the revenue beat. The company remains unprofitable, which could increase sensitivity to acquisition costs and future research spending. Tarsus Pharmaceuticals Reports Q2 Loss, Tops Revenue Estimates
• Negative Sentiment: Funding creates dilution: Tarsus announced an oversubscribed $125 million private placement to help support the Alkeus transaction and growth initiatives. While the financing improves liquidity, issuing new shares dilutes existing holders. Investors may also be concerned that insiders reported selling shares, with no purchases, during the past six months. Tarsus Pharmaceuticals Announces $125 Million Private Placement

Tarsus Pharmaceuticals Company Profile

Tarsus Pharmaceuticals, Inc is a clinical‐stage biopharmaceutical company focused on developing novel therapies for diseases of the eye and ocular surface. The company’s research platform centers on neuro‐effector modulation to address underlying disease mechanisms rather than solely treating symptoms. Tarsus’s lead candidate, OC-01 (varenicline solution), is an intranasal formulation in Phase 3 development for the treatment of dry eye disease, a condition affecting millions worldwide and associated with significant patient discomfort and reduced quality of life.

In addition to its dry eye program, Tarsus is advancing preclinical and early‐stage programs targeting other ophthalmic indications, including allergic conjunctivitis and retinal disorders.